RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers

RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization, has announced a strategic partnership with BlueRock Therapeutics, a leader in stem cell therapeutic development, to broaden access to clinical-grade pluripotent stem cell lines for cell therapy developers.

Through the partnership, RoslinCT will augment its existing pluripotent cell therapy offering to include access to BlueRock’s clinical-grade induced pluripotent stem cell lines, alongside RoslinCT’s own cell lines and related services. This expanded offering will provide developers with a more comprehensive set of tools and support to accelerate their pluripotent cell-based therapies from early development toward the clinic and commercial manufacture.

Under the agreement, RoslinCT will enable access to matched research-grade samples of BlueRock’s cell lines for prospective customers, while BlueRock will maintain oversight of commercial licensing. RoslinCT and BlueRock have also completed a technical transfer of the cell lines to RoslinCT’s facilities and team, enabling RoslinCT to support customers with services including cell banking, process and analytical development, and the manufacture of drug products for clinical and commercial use.

Peter Coleman, Chief Executive Officer of RoslinCT, said: “Pluripotent cell-based therapies are increasingly advancing in the clinic and show promise for cost-effective therapies for a broad range of conditions. We are pleased to partner with BlueRock to further strengthen RoslinCT’s pluripotent cell therapy offering. By adding access to BlueRock’s clinical-grade lines alongside our own cell lines and development and manufacturing capabilities, we can provide customers with a more comprehensive pathway to support the development of advanced therapies from early-stage evaluation through to clinical and commercial supply.”

“At BlueRock, we have invested significantly in developing clinical-grade pluripotent stem cell capabilities to support our own therapeutic programs,” said Greg Motz, Vice President of Research at BlueRock Therapeutics. “We are pleased to make these cell lines available through RoslinCT, helping provide cell therapy companies with additional resources to advance their therapies toward the clinic.”

RoslinCT supports cell therapy developers with capabilities spanning process and analytical development, cell banking, gene editing, differentiation, GMP manufacturing, and commercial supply across autologous, allogeneic, and pluripotent cell therapy platforms.